Methods for production of oxygenated terpenes
The present disclosure relates to methods for producing oxygenated terpenoids, and preparation of compositions and formulations thereof. Polynucleotides, derivative enzymes, and host cells for use in such methods are also provided.
1. A formulation, comprising:
nootkatone, wherein the nootkatone is present in the formulation in an amount ranging from about 55% to about 60% (w/w);
α-nootkatol, wherein the α-nootkatol is present in the formulation in an amount ranging from about 20% to about 25% (w/w); and
β-nootkatol, wherein the β-nootkatol is present in the formulation in an amount ranging from about 5% to about 10% (w/w).
2. The formulation of claim 1 , wherein at least one of the nootkatone, the α-nootkatol, and the β-nootkatol, is produced using a biosynthetic process.
3. The formulation of claim 1 , wherein the nootkatone, the α-nootkatol, and the β-nootkatol, are produced using at least one biosynthetic process.
4. The formulation of claim 1 , wherein the formulation is a natural flavor formulation.
5. The formulation of claim 1 , further comprising one or more non-sesquiterpene components or sesquiterpene components.
6. The formulation of claim 5 , wherein the one or more non-sesquiterpene components or sesquiterpene components is selected from Table 8A, products obtained from oxidation of valencene by the cytochrome P450 enzyme Stevia rebaudiana Kaurene Oxidase (SrKO).
7. The formulation of claim 1 , further comprising valencene.
8. The formulation of claim 7 , wherein the valencene is present in the formulation in an amount ranging from about 5% to about 10% (w/w).
9. The formulation of claim 7 , wherein at least one of the nootkatone, the α-nootkatol, the β-nootkatol, and the valencene is produced using a biosynthetic process.
10. The formulation of claim 7 , wherein the nootkatone, the α-nootkatol, the β-nootkatol, and the valencene are produced using at least one biosynthetic process.
11. The formulation of claim 8 , wherein the formulation is a natural flavor formulation.
12. The formulation of claim 8 , further comprising one or more non-sesquiterpene components or sesquiterpene components.
13. The formulation of claim 12 , wherein the one or more non-sesquiterpene components or sesquiterpene components is selected from products obtained from oxidation of valencene by the cytochrome P450 enzyme SrKO.